SUMMARY Background
High-quality data on the management of autoimmune hepatitis (AIH) are scarce. Despite published guidelines, management of AIH is still expert based rather than evidence based.
Aim
To survey expert hepatologists, asking each to describe their practices in the management of patients with AIH.
Methods
A survey questionnaire was distributed to members of the International AIH Group. The questionnaire consisted of four clinical scenarios on different presentations of AIH.
Results
Sixty surveys were sent, out of which 37 were returned. None reported budesonide as a first line induction agent for the acute presentation of AIH. Five (14%) participants reported using thiopurine S-methyltransferase measurements before commencement of thiopurine maintenance therapy. Thirteen (35%) routinely perform liver biopsy at 2 years of biochemical remission. If histological inflammatory activity is absent, four (11%) participants reduced azathioprine, whereas 10 (27%) attempted withdrawal altogether. Regarding the management of difficult-to-treat patients, mycophenolate mofetil is the most widely used second-line agent (n =~450 in 28 centres), whereas tacrolimus (n =~115 in 21 centres) and ciclosporin (n =~112 in 18 centres) are less often reported. One centre reported considerable experience with infliximab, while rescue therapy with rituximab has been tried in seven centres.
Conclusions
There is a wide variation in the management of patients with autoimmune hepatitis even among the most expert in the field. Although good quality evidence is lacking, there is considerable experience with second-line therapies. Future prospective studies should address these issues, so that we move from an expertto an evidence-and personalised-based care in autoimmune hepatitis. 
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INTRODUCTION
Autoimmune hepatitis (AIH) is a severe life threatening chronic progressive immune-mediated inflammatory disorder of the liver. 1 AIH is a relatively rare disease, although its incidence has risen in recent years. 2 It affects both children and adults, and is characterised by hypergammaglobulinaemia, circulating autoantibodies and interface hepatitis. 3 Women are more often affected than men (ratio: 4:1). 3 AIH is a very heterogeneous disease with a variety of clinical presentations, ranging from asymptomatic liver biochemical abnormalities to acute severe hepatitis or even acute liver failure. 4 There is no single diagnostic test for AIH; and diagnosis is based upon several indicative clinical, biochemical, serological and histological findings. 5 Currently, two diagnostic scoring systems, the revised original (1999) and the simplified (2008) criteria, have been published by the International Autoimmune Hepatitis Group. 6, 7 In all but the mildest form of AIH, irrespective of type of presentation, fibrosis is frequently present at diagnosis, and with advanced disease bridging fibrosis and cirrhosis are often seen. 1 Untreated, this condition has a poor outcome, with mortality rate of up to 40% reported. 1 Highquality data on the management of AIH are scarce, with therapeutic data largely informed by randomised trials published over four decades ago. [8] [9] [10] In addition, decisions regarding the use of second-line therapies are based on small series or even case reports, mostly reporting the experience of a limited number of centres with a special interest in AIH.
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Societies such as the American Association for the Study of the Liver (2010), the British Society of Gastroenterology (2011), and more recently the European Association for the Study of the Liver (2015) published guidelines, [12] [13] [14] which include recommendations pertaining to second-line therapies in AIH, based on the limited available data. Thus, expert opinion rather than evidence-based medicine remains a factor in the management of patients with AIH. 15 The present study was designed to explore the current practices on the management of AIH of a panel comprising international expert hepatologists with extensive experience in AIH in order to help design and inform future prospective studies.
METHODS
Study design
We developed a survey questionnaire to assess the practices of an international panel of expert hepatologists on the clinical management of AIH. The participants were selected if the following criteria were met: current membership of the International Autoimmune Hepatitis Group, active practice of adult patients with AIH and expertise in AIH based on a relevant track record of publications in AIH within the last 3 years. The survey was initially distributed and tested among 15 members of the International Autoimmune Hepatitis Group who fulfilled the aforementioned criteria at their biannual meeting in Vienna in April 2015. In addition, the questionnaire was made available online, and an e-mail link to the survey was sent to further 45 experts in August 2015, followed by a total of three weekly reminders. Participants were asked to provide details on their clinical practice: number of years in practice, centre, country, approximate number of AIH patients, whether or not working at a transplant centre.
Questionnaire
The questionnaire consisted of four clinical scenarios on different presentations of AIH on which 37 questions were asked (Data S1, https://www.surveymonkey.com/r/ Clin_manag_AIH). Briefly, cases consisted of a short history and results from diagnostic work-up, in short representing a 'standard' presentation of a 32-year-old woman (Case 1), follow-up on the management of a 44-year-old woman with nonresponse to standard therapy after 1 year (Case 2), a 44-year-old man with intolerance to standard therapy requiring second-line therapy (Case 3) and a 25-year-old woman with acute liver failure due to AIH (Case 4). Answers to the provided questions were offered as integer multiple choice, allowing for a free text alternative (other).
Data presentation and analysis
Data were collected non-anonymously and analysed using the graphical and analytical features of www.survey monkey.com and Microsoft Excel 2010 (Microsoft Corporation, Washington, USA). Answers are described as counts and percentages for categorical variables. In addition, we compared the group of respondents working at a transplant centre with the group of respondents working at a nontransplant centre regarding the experience with second-line agents as well as the management of acute severe to acute liver failure due to AIH.
Ethical considerations
This study was conducted according to the Declaration of Helsinki. All authors reviewed and approved the final manuscript.
RESULTS
Participants
A total of 60 surveys were sent to the International Autoimmune Hepatitis Group members fulfilling the criteria mentioned above, out of which 37 (62%) were returned. All 37 respondents answered every question. Eighteen countries on five different continents were represented. The number of AIH patients treated by the participating physicians ranged from <20 in 2 (5%) to >200 in 17 (46%). Twenty-five respondents (68%) had >20 years of experience and 24 (65%) were active in a transplant centre. There were no differences in terms of number of AIH patients or years of experience between respondents working at a transplant vs. nontransplant centres. Table 1 summarises the characteristics of respondents.
Induction therapy
Thirty-three participants reported commencing induction therapy in a patient with acute AIH and a weight of 75 kg with predniso(lo)ne in isolation. The preferred daily dose of predniso(lo)ne differed markedly among participants [20 mg: n = 1, 30 mg: n = 1, 40 mg: n = 15, 60 mg: 12, 75 mg (1 mg/kg): n = 3 and 100 mg: n = 1]. Three participants reported to start with predniso(lo)ne 30 mg/day and simultaneously add azathioprine (AZA) at 1 mg/kg/day, whereas another reported to start with predniso(lo)ne 75 mg/day and mycophenolate mofetil 1 g twice per day. Thirty-six participants would taper prednisolone dose over the next 3 months to minimal possible dose (n = 25) or a daily dose of 10 mg/day (n = 1). Of note, none of the participants reported the use of budesonide as a first-line induction agent for the acute presentation of AIH. The majority (n = 32) would subsequently introduce AZA maintenance therapy (n = 22) while tapering steroids (n = 10) commencing this strategy between 2 and 10 weeks after initiation of induction therapy. Only five (14%) participants reported the routine use of thiopurine S-methyltransferase measurements before starting thiopurine therapy. However, 13 (35%) participants monitored compliance by measuring 6-thioguaninenucleotide levels. Fourteen (38%) perform routine measurements of autoantibody titres during follow-up.
Treatment withdrawal
Thirteen (35%) participants reported that they routinely perform a liver biopsy at 2 years of stable biochemical remission. In the presented case (Case 1), 14 participants (38%) would have performed liver biopsy when the patient was in stable biochemical remission. If histological inflammation and severe fibrosis or cirrhosis are absent in a 2-year treatment evaluation biopsy, four (11%) participants would attempt reduction of AZA, whereas 10 (27%) attempt withdrawal altogether.
Other consideration regarding management Twenty-nine participants (78%) reported that they routinely use Fibroscan (Echosens, Paris, France) for noninvasive assessment of fibrosis during follow-up of their patients. Twenty-five participants (68%) routinely perform DEXA scan to check for the development of osteoporosis during follow-up. A minority of respondents (n = 14, 38%) perform routine measurements of auto-antibody titres during follow-up.
Second-line therapy in nonresponse and intolerance
The respondents were asked to provide the approximate number of patients that were treated with six medications that are considered as second-line therapy by society guidelines. Overall, the large majority of hepatologists (n = 31) reported to have any experience with second-line medication in the management of AIH. Mycophenolate mofetil is the most widely used secondline agent (n =~450, 28 centres). Tacrolimus (n =~115, 21 centres) and ciclosporin (n =~112, 18 centres) are less often reported. One centre reported experience with infliximab (n = 12). Rescue therapy with rituximab has been attempted (but not published) in seven centres (n =~22). Most of the experience with second-line therapy using ciclosporin and tacrolimus resides in the larger tertiary referral centres with a transplant programme, but these agents are also used in small numbers in nontransplant centres (Figure 1 ).
Liver transplantation and immune suppression
In two cases, the 44-year-old man with intolerance to standard therapy requiring second-line therapy (Case 3) and a 25-year-old woman with acute liver failure due to AIH (Case 4), the respondents were asked about the assessment and/or referral for liver transplantation. Case 3 continued to have severe liver biochemical abnormalities with sign of deteriorating liver function tests (INR 1.4. Albumin was 32 g/L) 6 months after tacrolimus (4 mg/day) was added while maintaining prednisolone 20 mg/day and mycophenolate mofetil 2 g/day. Twentythree respondents said they would assess the patient for liver transplantation, whereas nine answered that they would maintain the current regimen (n = 3) or consider alternative immunosuppressive therapy (n = 6). Of these 23 respondents, 11 answered that they would maintain the current immunosuppressive regimen, whereas seven opted for reducing immunosuppression in preparation of liver transplantation. Five respondents chose to the therapeutic option of Infliximab or rituximab salvage therapy while assessing the patient for liver transplantation. Case 4 presented with acute onset of jaundice, had a model for end-stage liver disease score of 23 [ALT 2700, AST 2103, AP 146 IU/L, total bilirubin 237 lmol/L (13.8 mg/dL) and albumin levels of 2.9 g/dL, INR 1.6] and a liver biopsy showing 'complete collapse of the parenchyma'. Twenty-nine respondents would start induction therapy with predniso(lo)ne with (n = 4) or without (n = 25) AZA. Nine respondents would refer the patient immediately for liver transplantation, only one of which would avoid treating the patient with any immunosuppressant. In this phase, the reported choice of induction therapy mostly consisted of high-dose steroid therapy with either predniso(lo)ne 1 mg/kg/day (n = 11), methylprednisolone intraveneously 1 g/day for 3 days (n = 9), 60 mg prednisolone/day (n = 2), 100 mg prednisolone/day (n = 2) or methylprednisolone IV 100 mg/ day for 7 days (n = 1). Upon further deterioration despite the institution of immunosuppressive therapy, 21 respondents would have assessed the patient for liver transplantation. The majority of these respondents (n = 13) would maintain the immunosuppressive regimen in preparation of transplantation, whereas nine respondents would start to reduce immunosuppression. Thirteen participants (transplant n = 10; non-transplant n = 3) would immediately list the patient for liver transplantation if encephalopathy was present at that stage. 
DISCUSSION
This survey shows that predniso(lo)ne remains the preferred agent for induction of remission in newly diagnosed patients with AIH. Moreover, there is a lack of consensus among expert hepatologists regarding both the initial management and follow-up of patients with AIH. In addition, and despite the lack of good quality evidence, there is considerable experience within the field albeit largely unreported in relation to second-and third-line therapies for difficult-to-treat AIH patients. All experts surveyed routinely use predniso(lo)ne as initial treatment for AIH, but there is a wide variation in the dose and time that is taken to taper the dose. While a minority of respondents start therapy with a combination of prednisolone and AZA, the majority starts prednisolone in isolation only adding AZA once steroids are being tapered. These strategies reflect the differences regarding combination therapy between the 2010 American Association for the Study of the Liver guidelines and the 2015 European Association for the Study of the Liver guidelines; while the American Association for the Study of the Liver guideline recommends starting either a fixed dose of 50 mg/day or 1-2 mg/kg/day of AZA at the same time as steroids, 12 European Association for the Study of the Liver recommends 1-2 mg/kg/day of AZA to be started only 2 weeks after the introduction of steroids. 14 Whether one strategy has an advantage over the other is unknown, since studies addressing this question are currently not available. Interestingly, none of the respondents reported the use of budesonide as a first-line agent for induction of remission despite their inclusion as a therapeutic option in treatment na€ ıve patients in both British and European guidelines and the presence of randomised data in noncirrhotic patients. 16 Once remission (defined as normalisation of ALT, IgG levels as well as the absence of inflammatory activity in liver biopsy) is attained, AZA, either as monotherapy (European Association for the Study of the Liver guideline) or in combination with steroids (European Association for the Study of the Liver, American Association for the Study of the Liver and British Society for Gastroenterology guidelines), remains the preferred strategy for its maintenance. This is in line with a systematic review of randomised, controlled trials showing that maintenance therapy with AZA alone or in combination with prednisolone was superior to prednisolone monotherapy. 17 Interestingly, the recent budesonide trial, in which patients on the prednisolone arm were switched at 6 months to open-label budesonide, showed that combination of AZA with budesonide maintained remission while reducing the incidence of steroid-specific side effects. 16 Thus, it seems that the role of budesonide in AIH relies more on its efficacy as a maintenance drug in noncirrhotic patients who experience steroid side effects, rather than as a first-line induction agent. Although lack of response and toxicity are important issues regarding therapy with thiopurines, attempts to optimise treatment response and avoid the potential occurrence of side effects by thiopurine methyltransferase activity assessment or 6-thioguaninenucleotide (and 6-methylmercaptopurine) measurements is only done by a small minority of participants and does not appear to be the standard of care despite recent recommendations regarding the occurrence of cytopaenia (British Society for Gastroenterology guideline) and maintenance therapy with AZA during follow-up (European Association for the Study of the Liver guideline). It has been reported that, in the setting of inflammatory bowel disease, concerns over thiopurines toxicity often lead to cautious dosing strategies, with an impact in the time taken to achieve remission and overall outcome, including a higher risk of patients being started on other medications unnecessarily. 18 In addition, one recent study has
shown that thiopurine therapy in inflammatory bowel disease could be optimised and individualised, according to 6-thioguaninenucleotide levels enabling effective treatment decisions and improving clinical outcomes. 19 In AIH, this strategy may also be possible as 6-thioguaninenucleotide levels are also associated with remission and the metabolism of thiopurines may effectively be optimised with allopurinol in intolerant as well as nonresponsive patients. 20, 21 This suggests that strategies that would permit thiopurine dosing personalization beyond weight have the potential to improve outcomes in AIH and require further prospective studies. Attempts to withdraw treatment in noncirrhotic patients with stable biochemical remission for 2-3 years may be attempted, and maintenance of remission after treatment withdrawal is possible in some patients. 22 Since up to 50% of patients who have attained biochemical remission (i.e. normalisation of AST and IgG levels) still have histological inflammatory activity, 23 a confirmatory follow-up liver biopsy should be considered. 14 In this regard, 35% of the respondents reported to perform a biopsy after remission is attained and before attempting treatment withdrawal. If histological remission is confirmed, then one-third of those participants favour thiopurine dose de-escalation with the remaining twothirds attempting withdrawal altogether. Although no study comparing these two strategies is available, a For patients who fail to achieve remission on standard immunosuppression, proposed alternative therapies are based on scarce published data, mainly in the form of case reports or small case series (Table 2) . 21, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] Nevertheless, this study shows that among experts there is now ample experience with second-line agents, in particular with mycophenolate mofetil. Although patient with insufficient or no response to AZA typically do not respond satisfactorily to mycophenolate mofetil, the reported 33 but currently there is no head-to-head comparison with AZA as a first-line maintenance agent. The experience with calcineurin-inhibition, immunosuppressive agents used in organ transplantation mainly resides within the liver transplant centres. Taken together, the data suggest that patients who are AZA intolerant and therefore are candidates for mycophenolate mofetil as second-line can still be managed at tertiary nontransplant centres, while for those who do not respond with improvement of enzyme levels and model for end-stage liver disease score scores even after high-dose steroid induction (up to prednisone 100 mg/day) a second opinion regarding their management should be sought at a transplant centre (European Association for the Study of the Liver, American Association for the Study of the Liver and British Society for Gastroenterology guidelines). Despite recently published guidelines, there are great differences in the management of AIH patients, which emphasises the need for standardised definitions for therapeutic endpoints as well as new prospective (preferably randomised) studies (Table 3) . 43, 44 In conclusion, this study shows that there is a wide variation in the management of patients with AIH even among the most expert in the field, particularly concerning difficult-to-treat patients, possibly reflecting the poor quality of evidence available at the moment, and despite the published guidelines. Future prospective studies should address these issues, and for which transnational collaborations are urgently needed, so that we move from an expert-to an evidence-and personalised-based care in AIH (Table 3) .
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